Antiangiogeneic Activity of Annona Reticulata Seeds Extract

Authors

  • Bahir Abdul Razzaq Mshimesh Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, Baghdad, Iraq https://orcid.org/0000-0003-4412-8690
  • Israa falah Hassan Department of Pharmacology and Toxicology, College of Pharmacy, Mustansiriyah University, M.Sc. project, Baghdad, Iraq
  • Ahmed Majeed Al-Shammari Department of Experimental Therapy, Iraqi Center for Cancer and Medical Genetic Research (ICCMGR), Mustansiriyah University, Baghdad, Iraq.

DOI:

https://doi.org/10.29409/ijcmg.v15i1.325

Keywords:

Antiangiogenesis, Annona reticulata, CAM, rat aorta ring assay

Abstract

Background: Annona reticulata used in traditional medicines for epilepsy, dysentery, constipation, cardiac problems and as
insecticide. Annona reticulata seeds extracts contain active acetogenins compounds.
Aim of study : The study aimed to investigate the possible antiangiogenic activity of Annona reticulata extracts.
Material and method: The sequential extraction process with two solvents used to extracts grinded seeds of A. reticulata in the
following order according to increment in polarity: n-hexane and ethanol.CAM assay and Ex-vivo rat aorta assay was used to
identify the antiangiogeneic activity of both extracts and determine the most biological active extract.
Results: According to CAM assay, there was a statistically higher percent of inhibition zone during exposure to bevacizumab and the two extracts of A. reticulata at both concentrations when compared with DMSO, as a negative control group
(p-value ≤ 0.05). Meanwhile, n-hexane extract at only higher concentration (500 µg/5µl) showed a significantly greater zone
of inhibition compared with bevacizumab group (p-value ≤ 0.05).Data of rat aorta rings assay that represented as mean of
blood vessels growth inhibition revealed a statistically higher percentage of inhibition in bevacizumab and both extracts of A.
reticulata treated group compared with negative control group (p-value ≤ 0.05). In this study, the percent of growth inhibition
after exposure to n-hexane was approach to that of bevacizumab, where no significant difference was observed between both
groups (p-value > 0.05), while group that treated with ethanol extract showed statistically lower percent of growth inhibition
compared with n-hexane and bevacizumab treated groups (p-value ≤ 0.05). The results of this assay for the five concentrations
of ethanol and n-hexane extract showed a significant reduction in blood vessels growth in a concentration- dependent manner
(P ≤ 0.05) compared with negative control. The IC50, n-hexane was 74.95µg/ml while the value of IC50 for ethanol 95.89

Downloads

Published

2022-06-01

Issue

Section

Cancer Research